louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05251350: Incarcerated Right Inguinal Hernia Containing Sigmoid Colon: An Unusual Case Report
Official title: Incarcerated Right Inguinal Hernia Containing Sigmoid Colon: An Unusual Case Report
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Incarcerated Inguinal Hernia
Keywords: Incarcerated right inguinal hernia, right side, sigmoid colon
Lead sponsor: Kabul University of Medical Sciences
Sponsor class: OTHER
First posted: 2022-02-22
Enrollment: 2717
Sex: MALE
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: An incarcerated right inguinal hernia containing sigmoid colon.

Brief summary: Incarcerated inguinal hernia is an irreducible but the blood supply to the contained part is intact, but developing towards strangulation. Here the lumen of the portion of colon occupying a hernia sac is blocked with faeces.

Detailed description: A special data collection sheet designed to collect data regarding the diagnosis, age, sex and treatment from the profile of patient retrospectively. Data entry was performed by using Microsoft Excel and all the data were analysed by SPSS.

Eligibility criteria: Inclusion Criteria:

* inguinal hernia that requires emergency operation

Exclusion Criteria:

* hernia does not need emergency operation.

Primary outcomes:
measure: Frequency of incarcerated right inguinal hernia containing sigmoid colon
timeFrame: 2013-2021
Secondary outcomes:
Other outcomes:
Locations:
city: Kabul
country: Afghanistan
facility: Ahmadullah Danish
Study officials:
References:
Clinical trial NCT00345150: Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls
Official title: Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Keywords: hypertension
nitric oxide
renal hemodynamics
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2006-06-27
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The study tests the hypothesis that systemic and renal nitric oxide synthesis is changed in essential hypertension by investigating the effects of a non selective nitric oxide inhibitor on renal hemodynamics and sodium excretion in patients with essential hypertension. The results are compared with a group of healthy subjects.

Detailed description: The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:

1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
2. renal sodium excretion
3. lithium clearance and fractional lithium excretion
4. plasma levels of vasoactive hormones
5. blood pressure and heart rate

Eligibility criteria: Inclusion Criteria:

* Essential hypertension (blood pressure \> 140/90) with no signs of secondary hypertension
* P-creatinine \< 200 µmol/L

Exclusion Criteria:

* Anamnestic or clinical signs of heart disease, renal disease, liver disease, neoplastic disease, anemia or cerebro-vascular insult
* Medication except antihypertensives
* Drug or alcohol abuse
* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
name: Jesper N Bech, MD, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Holstebro Hospital, 7500 Holstebro, Denmark
name: Erling B Pedersen, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT04039750: Use of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis
Official title: Use of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Perforated Appendicitis
Lead sponsor: Prisma Health-Upstate
Sponsor class: OTHER
First posted: 2019-07-31
Enrollment: 200
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be randomized into 1 of 2 groups. Group "A" will be Antibiotic Irrigation with suction and Group "B" will be Suction Alone.
Primary purpose: TREATMENT

Brief summary: The proposed study will investigate whether antibiotic irrigation using a gentamicin/clindamycin solution during laparoscopic appendectomy is superior in preventing postoperative wound infections and IAA in perforated appendicitis compared to suction without irrigation. This will be the first prospective study to compare these two options in pediatric PA.

Detailed description: This study is for pediatric patients who are having an appendectomy and have a perforated appendix. The purpose of this study is to see whether antibiotic irrigation using gentamicin, clindamycin and suction during the surgery works better when compared to suction alone when cleaning the stomach cavity.

Arm A patients will have their abdomen irrigated with the antibiotics, gentamycin and clindamycin, and then the wound will be suctioned out. Arm B patients will not have the antibiotic irrigation but will have their wound suctioned.

Eligibility criteria: Inclusion Criteria:

1. Male or female, age 18 years or younger
2. Scheduled to undergo laparoscopic appendectomy
3. Preoperative or intra-operative diagnosis of perforated appendicitis (PA).
4. Willingness to undergo treatments, provide written informed consent, and participate in follow-up.

Exclusion Criteria:

1. Male or female older than 18 years of age
2. Declined to undergo laparoscopic appendectomy
3. Not willing to provide written informed consent or undergo randomization of treatment
4. Pregnancy

Primary outcomes:
measure: wound complications
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Greenville
country: United States
facility: Prisma Health - Upstate
state: South Carolina
Study officials:
affiliation: Prisma Health
name: Robert Gates, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00481650: Observational Trial With Leios/Alesse
Official title: A Prospective Observation Study (Anwendungsbeobachtung [AWB]) of the Prescribing and Administration Practices of German Gynecologists With Leios® Dragées/Alesse
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraceptives, Oral, Combined
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-06-04
Sex: FEMALE
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: A prospective, observational study (Anwendungsbeobachtung \[AWB\]) of the prescribing and administration practices of German gynecologists with Leios® Dragées.


Eligibility criteria: Inclusion Criteria:

* Healthy, women, aged under 40

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For Germany, medinfoDEU@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04437550: Effects of Exercise Intensity on Energy Intake, Appetite and Enjoyment in Overweight and Obese Females
Official title: Effects of Exercise Intensity on Energy Intake, Appetite and Enjoyment in Overweight and Obese Females
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Lead sponsor: Ohio University
Sponsor class: OTHER
Collaborators: name: Marywood University
First posted: 2020-06-18
Enrollment: 11
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Interval exercise involves short bouts of high intensity exercise interspersed with periods of lower intensity exercise. The benefit is that a shorter total duration of exercise may be required to achieve cardiovascular benefits similar to or even superior to traditional longer bouts of steady state endurance exercise. However how this type of exercise affects appetite and energy intake, particularly in overweight and obese females is not well known.

This study involves two trials of exercise, one at high intensity and one at low intensity, followed by a buffet lunch, in overweight and obese females.


Eligibility criteria: Inclusion Criteria:

1. Female
2. Adult
3. apparently healthy
4. overweight or class I obese
5. eumenorrheic

Exclusion Criteria:

1. Diabetes
2. pregnancy
3. cardiovascular disease
4. greater than 1 hour of structured physical activity per week
5. thyroid disease
6. polycystic ovary disease

Primary outcomes:
measure: Change in energy expenditure
timeFrame: immediately pre-breakfast, immediately pre-exercise, during exercise, and immediately post-exercise.
measure: Change in energy intake
timeFrame: immediately post exercise
measure: Change in appetite
timeFrame: immediately pre-breakfast, immediately post-breakfast, immediately post-exercise and immediately pre-lunch
measure: Change in subjective hunger
timeFrame: baseline, immediately pre-exercise, immediately post-exercise, immediately pre-lunch, and immediately post-lunch
Secondary outcomes:
Other outcomes:
Locations:
city: Scranton
country: United States
facility: Human Physiology Lab
state: Pennsylvania
Study officials:
References:
Clinical trial NCT06574750: Effect of a New HA Filler in Correcting Nasolabial Fold
Official title: New HA Filler Versus Juvederm for Nasolabial Fold Correction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging Problems
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2024-08-28
Enrollment: 74
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators aimed to evaluate the efficacy and safety of new HA filler for nasolabial fold correction

Detailed description: A 24-week prospective, single-center, assessor-blinded, randomized, split-face study was conducted to compare the clinical efficacy and safety of new HA filler versus Juvederm for nasolabial fold correction

Eligibility criteria: Inclusion Criteria:

* Patients who had prominent NLFs with a WSRS score of 3 or 4 on both sides

Exclusion Criteria:

* patients with active facial skin diseases or history of severe allergies, autoimmune disorders, or hypersensitivity to HA or any of the excipients contained in the investigational filler
* participants who had used a local topical preparation (steroid and retinoid) within 2 weeks before the study
* participants who had undergone chemical peeling, laser procedures, or acne treatments within 4 months before the study
* participants who had been injected with other biomaterials, including HA within 6 months before the study.

Primary outcomes:
measure: WSRS
timeFrame: at 24 weeks after treatment
Secondary outcomes:
measure: GAIS
timeFrame: at 24 weeks after treatment
measure: Adverse events related to the procedure
timeFrame: up to 24 weeks
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Bo Ri Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06807450: Repair of Oronasal Fistula Using Interpositional Buccal Pad of Fat as a Free Graft in a Cleft Palate Patient
Official title: Repair of Oronasal Fistula Using Interpositional Buccal Pad of Fat as a Free Graft in a Cleft Palate Patient
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Cleft Palate
Keywords: oro-nasal fistula
cleft palate
buccal pad of fat free graft
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-02-04
Enrollment: 36
Sex: ALL
Minimum age (years): 5
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 18 cleft palate patients had residual oronasal fistula included in this study divided randomly to two groups group I (control group): the fistula was repaired using two layers (oral and nasal layers) group II (study group): The fistula was repaired using two layers (oral and nasal layers ) with interpositional free buccal pad of fat graft between two layers

Detailed description: 18 cleft palate patients had residual oronasal fistula included in this study devided randomly to two groups group I (control group):the fistula was repaired using two layers nasal layer:closed by turn-in flaps, taken from around the margins of the fistula by making incision around margins of distance slightly larger than half of diameter of fistula bilaterally, then closed by inverted interrupted suture Vicry l 4/0.

oral layer:(Bardach two-flap palatoplasty) was used and raised on opposite sides of the cleft palate and brought together in the midline to create a continuous palate

group II (study group): The fistula was repaired using two layers (oral and nasal layers ) as group I with buccal pad of fat free graft was taken through veastibular incision at zygomatic buttress then blunt dissection to get buccal fat which was released from its pedicle and inserted between oral and nasal layers.

Eligibility criteria: Inclusion Criteria:

* cleft palate patients with oro-nasal fistula fistula in hard palate

Exclusion Criteria:

* syndromatic patients

Primary outcomes:
measure: evaluation of wound healing
timeFrame: one month
measure: recurrence of oro-nasal fistula
timeFrame: one -3 months
Secondary outcomes:
measure: postoperative pain
timeFrame: one month
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Dentistry, Tanta University
Study officials:
affiliation: Tanta University
name: mona s sheta, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02453750: Airway Inflammation in Congenital Diaphragmatic Hernia Patients
Official title: Investigation of Airway Inflammation in Congenital Diaphragmatic Hernia Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congenital Diaphragmatic Hernia
Keywords: Congenital Diaphragmatic Hernia
Airway Inflammation
Asthma
Hypersaline
Pediatrics
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
First posted: 2015-05-25
Enrollment: 21
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: We propose to examine Congenital Diaphragmatic Hernia (CDH) patients for evidence of airway inflammation as a first step to characterize the reported bronchodilator responsiveness. Airway biopsy studies are invasive and thus we propose to perform induced sputum studies to document the amount and type of inflammation present. Another ancillary non-invasive measure of airway inflammation that we will use is exhaled nitric oxide (NO). The primary objective of this study is to determine if CDH patients have any evidence of airway inflammation. The hypothesis of this study is that children with CDH do not have evidence of airway inflammation associated with bronchodilator responsiveness. Based on this information, treatment for CDH patients will hopefully be more accurate and appropriate for their specific needs.


Eligibility criteria: Inclusion Criteria:

* 6 - 18 years of age at enrolment
* Clinically stable at enrolment
* Attending follow-up in the CDH Clinic at SickKids

Exclusion Criteria:

* Unable to perform pulmonary function testing
* Clinically unstable at enrolment
* Known hypersensitivity to salbutamol

Primary outcomes:
measure: Number of Participants With Elevated Sputum Eosinophils
timeFrame: post sputum induction
Secondary outcomes:
measure: Number of Participant With Elevated Sputum Neutrophils
timeFrame: Baseline, +30 minutes
measure: Number of Participant With Elevated Exhaled Nitric Oxide (NO) Level
timeFrame: 30 min
measure: Number of Participant With Bronchodilator Response
timeFrame: life time of child (age 6 to present age)
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children
name: Theo Moraes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06534450: The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics
Official title: A Comparative Randomized Placebo (Sham Pheresis) Controlled Clinical Trial To Evaluate The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Aging
Keywords: Therapeutic Plasma Exchange
Lead sponsor: Global Apheresis, Inc.
Sponsor class: INDUSTRY
Collaborators: name: CIRCULATE, Inc.
First posted: 2024-08-02
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty individuals. The main question is to assure the safety from long term TPE using changes in clinical and laboratory outcomes and also evaluating changes on additional blood biomarkers and epigenetic clocks during and after TPE treatment. Researchers will compare the TPE treatment group to the Sham treatment group to identify changes due to TPE. Participants will receive six TPE or Sham treatments over one of two treatment schedules and may receive IVIG with treatment.


Eligibility criteria: Inclusion Criteria:

* Subjects over 50 years of age with or without chronic inflammatory condition

Exclusion Criteria:

* Poor peripheral vascular access
* Diagnosis of active malignancy
* Late-stage Alzheimer's disease Any medical condition which may deteriorate because of plasma exchange procedures. These include, but are not limited to, symptomatic coronary artery disease, congestive heart failure and restrictive pulmonary disease (COPD). The investigators reserve the right to exclude anyone they feel may be harmed in any way by participating in the trial.
* Presence of active infection
* Alcohol or drug dependency
* Psychiatric disorder that will interfere with participation in the study (e.g., schizophrenia, bipolar disorder)

Primary outcomes:
measure: Adverse events and unanticipated events total for TPE safety
timeFrame: through study completion, an average of 1 year
measure: Rate of change to blood epigenetic clock from TPE
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Change in hand grip strength
timeFrame: after study completion, an average of 2 years
measure: Change in time up and go test
timeFrame: after study completion, an average of 2 years
measure: Change in balance time
timeFrame: after study completion, an average of 2 years
measure: Change in short-form health survey score
timeFrame: after study completion, an average of 2 years
Other outcomes:
Locations:
city: Mill Valley
country: United States
facility: Global Apheresis
state: California
Study officials:
affiliation: Global Apheresis
name: Dobri Kiprov, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00534950: Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carcinoma, Squamous Cell
Keywords: Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck
Lead sponsor: King Faisal Specialist Hospital & Research Center
Sponsor class: OTHER
First posted: 2007-09-26
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck


Eligibility criteria: Inclusion Criteria:

* Patients with SCC of the head and neck

Primary outcomes:
measure: safety
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: KFSH&RC
Study officials:
affiliation: KFSH&RC
name: Nasser Al Rajhi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04369950: Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine
Official title: Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Physiological Effect of Drugs
Morphine
Analgesics
Analgesics, Opioid
Central Nervous System Depressants
Narcotics
Keywords: cesarean delivery
c-section
chloroprocaine
lidocaine
morphine
post-operative pain
post-cesarean analgesia
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2020-04-30
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to show that the effect of 3% 2-chloroprocaine prior to epidural morphine administration will be not inferior to the effect of epidural 2% lidocaine with 1:200,000 epinephrine on total opioid use for 24h


Eligibility criteria: Inclusion Criteria:

* pregnant patients
* live singleton pregnancy

Exclusion Criteria:

* BMI \>40
* obstructive sleep apnea
* drug abuse
* chronic pain
* chronic opioid use
* nonfunctioning epidural

Primary outcomes:
measure: Total Amount of Opioid Used
timeFrame: 24 hours after epidural morphine administration
Secondary outcomes:
measure: Total Amount of Opioid Used
timeFrame: 12 hours after epidural morphine administration
measure: Total Amount of Opioid Used
timeFrame: 8 hours after epidural morphine administration
measure: Total Amount of Opioid Used
timeFrame: 4 hours after epidural morphine administration
measure: Pain as Measured by a 11 Point Verbal Scale
timeFrame: 4,8, 12 and 24 hours after epidural morphine administration
measure: Number of Participants Who Had Mild, Moderate or Severe Nausea as Measured by a 3 Point Scale
timeFrame: 4,8, 12 and 24 hours after epidural morphine administration
measure: Number of Participants Who Had Mild, Moderate or Severe Pruritis as Measured by a 3 Point Scale
timeFrame: 4,8, 12 and 24 hours after epidural morphine administration
measure: Time Until First Opioid Request
timeFrame: Up to 48 hours after epidural morphine administration
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Linden Lee, MD
role: PRINCIPAL_INVESTIGATOR
References: